A comprehensive review of genetic association studies

Most common diseases are complex genetic traits, with multiple genetic and environmental components contributing to susceptibility. It has been proposed that common genetic variants, including single nucleotide polymorphisms (SNPs), influence susceptibility to common disease. This proposal has begun to be tested in numerous studies of association between genetic variation at these common DNA polymorphisms and variation in disease susceptibility. We have performed an extensive review of such association studies. We find that over 600 positive associations between common gene variants and disease have been reported; these associations, if correct, would have tremendous importance for the prevention, prediction, and treatment of most common diseases. However, most reported associations are not robust: of the 166 putative associations which have been studied three or more times, only 6 have been consistently replicated. Interestingly, of the remaining 160 associations, well over half were observed again one or more times. We discuss the possible reasons for this irreproducibility and suggest guidelines for performing and interpreting genetic association studies. In particular, we emphasize the need for caution in drawing conclusions from a single report of an association between a genetic variant and disease susceptibility.

[1]  N. Risch.  Searching for genetic determinants in the new millennium , 2000, Nature.

[2]  Johan Auwerx,et al.  A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity , 1998, Nature Genetics.

[3]  E S Lander,et al.  The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. , 2000, Nature genetics.

[4]  J. Haines,et al.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. , 1997, JAMA.

[5]  Freely associating , 1999, Nature Genetics.

[6]  M. Daly,et al.  A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms , 2001, Nature.

[7]  K. Clément,et al.  The Pro115Gln and Pro12Ala PPAR gamma gene mutations in obesity and type 2 diabetes , 2000, International Journal of Obesity.

[8]  K. Marder,et al.  The APOE- (cid:101) 4 Allele and the Risk of Alzheimer Disease Among African Americans, Whites, and Hispanics , 2001 .

[9]  B. Dahlbäck,et al.  Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[10]  T. Kadowaki,et al.  The Pro12Ala Polymorphism in PPAR γ2 May Confer Resistance to Type 2 Diabetes , 2000 .

[11]  Pieter H. Reitsma,et al.  Mutation in blood coagulation factor V associated with resistance to activated protein C , 1994, Nature.

[12]  D. Altshuler,et al.  Genetic polymorphisms and disease. , 1998, The New England journal of medicine.

[13]  O. Gureje,et al.  Lack of an association between apolipoprotein E ϵ4 and Alzheimer's disease in elderly nigerians , 1995 .

[14]  M. Norusis,et al.  Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. , 1991, American journal of human genetics.

[15]  M. Kasuga,et al.  The Pro12 -->Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. , 2001, Diabetes.

[16]  G. Morgan,et al.  Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[17]  M. Margaglione,et al.  The Methylenetetrahydrofolate Reductase TT677 Genotype Is Associated with Venous Thrombosis Independently of the Coexistence of the FV Leiden and the Prothrombin , 1998, Thrombosis and Haemostasis.

[18]  R. Matthews,et al.  A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase , 1995, Nature Genetics.

[19]  J. Haines,et al.  Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .

[20]  W. Ewens,et al.  Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). , 1993, American journal of human genetics.

[21]  N E Morton,et al.  Tests and estimates of allelic association in complex inheritance. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[22]  E. Lander,et al.  Genetic dissection of complex traits science , 1994 .

[23]  M. den Heyer,et al.  Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida , 1995, The Lancet.

[24]  O. Gureje,et al.  Lack of an association between apolipoprotein E epsilon 4 and Alzheimer's disease in elderly Nigerians. , 1995, Annals of neurology.

[25]  P. Reitsma,et al.  Thermolabile Methylenetetrahydrofolate Reductase and Factor V Leiden in the Risk of Deep-Vein Thrombosis , 1998, Thrombosis and Haemostasis.

[26]  D. Reich,et al.  Detecting association in a case‐control study while correcting for population stratification , 2001, Genetic epidemiology.

[27]  B. Dahlbäck,et al.  Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the factor V gene. , 1996, The Biochemical journal.

[28]  D. Steinberg,et al.  Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[29]  W. Willett,et al.  Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. , 1996, Circulation.

[30]  V. Colantuoni,et al.  Pro12Ala substitution in the peroxisome proliferator-activated receptor-gamma2 is not associated with type 2 diabetes. , 1999, Diabetes.

[31]  L. Cardon,et al.  Association study designs for complex diseases , 2001, Nature Reviews Genetics.

[32]  P. Frosst,et al.  Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. , 1996, American journal of human genetics.

[33]  J. Pritchard,et al.  Use of unlinked genetic markers to detect population stratification in association studies. , 1999, American journal of human genetics.

[34]  A. Chakravarti.  Population genetics—making sense out of sequence , 1999, Nature Genetics.

[35]  A. Evans,et al.  Homocysteine and risk of premature coronary heart disease. Evidence for a common gene mutation. , 1996, Circulation.

[36]  W. Willett,et al.  Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. , 1997, Cancer research.

[37]  D. Weatherall,et al.  The Principles of Human Biochemical Genetics , 1975 .

[38]  J. Burn,et al.  Susceptibility to spina bifida; an association study of five candidate genes , 1998, Annals of human genetics.

[39]  F. Collins,et al.  The peroxisome proliferator-activated receptor-gamma2 Pro12A1a variant: association with type 2 diabetes and trait differences. , 2001, Diabetes.

[40]  J F Gregory,et al.  Polymorphisms of methylenetetrahydrofolate reductase and other enzymes: metabolic significance, risks and impact on folate requirement. , 1999, The Journal of nutrition.

[41]  J. Auwerx,et al.  Impact of the Peroxisome Proliferator Activated Receptor γ2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus , 2000, International Journal of Obesity.

[42]  D C Shields,et al.  A genetic defect in 5,10 methylenetetrahydrofolate reductase in neural tube defects. , 1995, QJM : monthly journal of the Association of Physicians.

[43]  S. Engeli,et al.  Pro12Ala missense mutation of the peroxisome proliferator activated receptor gamma and diabetes mellitus. , 1999, Biochemical and biophysical research communications.

[44]  K. Roeder,et al.  Genomic Control for Association Studies , 1999, Biometrics.

[45]  P. Donnelly,et al.  Association mapping in structured populations. , 2000, American journal of human genetics.

[46]  T. Kadowaki,et al.  The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. , 2000, Biochemical and biophysical research communications.

[47]  N. Wenger,et al.  Prevalence of the prothrombin 20210 G-to-A variant in blacks: infants, patients with venous thrombosis, patients with myocardial infarction, and control subjects. , 1998, The Journal of laboratory and clinical medicine.